Next Article in Journal
A Pathological Study of Acute Pulmonary Toxicity Induced by Inhaled Kanto Loam Powder
Next Article in Special Issue
miR-214-Dependent Increase of PHLPP2 Levels Mediates the Impairment of Insulin-Stimulated Akt Activation in Mouse Aortic Endothelial Cells Exposed to Methylglyoxal
Previous Article in Journal
Changes in the Distribution of Cocaine- and Amphetamine-Regulated Transcript-Containing Neural Structures in the Human Colon Affected by the Neoplastic Process
Previous Article in Special Issue
Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models
Open AccessReview

Glyoxalases in Urological Malignancies

Department of Experimental Medicine, University of Perugia, 06132 Perugia, Italy
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(2), 415;
Received: 19 December 2017 / Revised: 25 January 2018 / Accepted: 26 January 2018 / Published: 31 January 2018
(This article belongs to the Special Issue Glyoxalase System in Health and Disease 2017)
Urological cancers include a spectrum of malignancies affecting organs of the reproductive and/or urinary systems, such as prostate, kidney, bladder, and testis. Despite improved primary prevention, detection and treatment, urological cancers are still characterized by an increasing incidence and mortality worldwide. While advances have been made towards understanding the molecular bases of these diseases, a complete understanding of the pathological mechanisms remains an unmet research goal that is essential for defining safer pharmacological therapies and prognostic factors, especially for the metastatic stage of these malignancies for which no effective therapies are currently being used. Glyoxalases, consisting of glyoxalase 1 (Glo1) and glyoxalase 2 (Glo2), are enzymes that catalyze the glutathione-dependent metabolism of cytotoxic methylglyoxal (MG), thus protecting against cellular damage and apoptosis. They are generally overexpressed in numerous cancers as a survival strategy by providing a safeguard through enhancement of MG detoxification. Increasing evidence suggests that glyoxalases, especially Glo1, play an important role in the initiation and progression of urological malignancies. In this review, we highlight the critical role of glyoxalases as regulators of tumorigenesis in the prostate through modulation of various critical signaling pathways, and provide an overview of the current knowledge on glyoxalases in bladder, kidney and testis cancers. We also discuss the promise and challenges for Glo1 inhibitors as future anti-prostate cancer (PCa) therapeutics and the potential of glyoxalases as biomarkers for PCa diagnosis. View Full-Text
Keywords: Glyoxalases; urological malignancies; prostate cancer; kidney cancer; bladder cancer testicular cancer Glyoxalases; urological malignancies; prostate cancer; kidney cancer; bladder cancer testicular cancer
Show Figures

Figure 1

MDPI and ACS Style

Antognelli, C.; Talesa, V.N. Glyoxalases in Urological Malignancies. Int. J. Mol. Sci. 2018, 19, 415.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop